Bone Marrow Transplant — Understanding the Process & Types

They describe the same treatment. The goal is to replace unhealthy blood-forming stem cells with healthy ones. The term used simply reflects where the healthy cells come from. If cells are drawn directly from the bone marrow, it is often called a bone marrow transplant. If they are collected from the bloodstream after special injections, it is called a peripheral blood stem cell transplant. Cells can also come from umbilical cord blood. Today, most stem cells are collected from the bloodstream rather than the marrow itself, because it is gentler. Your oncologist will explain which method suits your situation and why, so there are no surprises.

An autologous transplant uses your own stem cells, which are collected and stored before high-dose chemotherapy, then returned to you. Because the cells are your own, there is no risk of graft-versus-host disease and the procedure is generally less risky. It is common in multiple myeloma and some lymphomas. An allogeneic transplant uses stem cells from a matched donor - often a sibling or an unrelated volunteer. The donor's new immune system can help fight any remaining cancer, but it carries a higher risk of complications, including graft-versus-host disease. The right choice depends on your diagnosis, age, marrow health and the availability of a good match. A specialist will guide this decision with you.

Matching is based on HLA markers - proteins on your cells - rather than blood group alone. Siblings are tested first because each brother or sister has about a one-in-four chance of being a full match. If no family member matches, doctors search unrelated donor registries for a volunteer with matching markers. A half-matched (haploidentical) donor, such as a parent or child, is now possible in many cases thanks to medical advances. Umbilical cord blood is another source, especially for children. A donor is usually a healthy adult who passes basic medical screening. The team explains every step to both patient and donor before anyone proceeds.

There is no single success rate, and any source promising a fixed figure should be treated with caution. Outcomes depend on your specific disease, how well it has responded to earlier treatment, your age, your overall health and the quality of the donor match. Autologous transplants for conditions like multiple myeloma often have favourable outcomes. Allogeneic transplants carry higher risks but can offer durable disease control in the right patient. The honest answer is that your oncologist can give you a realistic, personalised estimate only after reviewing your reports. At CION, we share truthful expectations and never make guarantees about cure or outcomes.

Recovery happens in stages. The first phase, called engraftment, is when the new stem cells settle into the marrow and begin making healthy blood cells. This usually takes about two to four weeks, most of which is spent in hospital with close monitoring. After discharge, blood counts, strength and appetite improve over the following months. Full recovery of the immune system can take a year or longer, especially after an allogeneic transplant. During this time, you are advised to protect yourself from infection and attend regular follow-up reviews. Recovery is different for everyone, and your care team will give you a timeline based on your progress.

The transplant day itself is not painful. The healthy stem cells are given through a drip into a vein, much like a routine blood transfusion. You stay awake and the infusion takes a short time. The harder parts of the journey are usually the high-dose chemotherapy beforehand and the recovery weeks afterward, when side effects such as fatigue, nausea, mouth soreness and low immunity are managed closely by the team. Pain relief and supportive care are provided throughout. We believe you deserve honest information, so we will explain each stage clearly, including what may be uncomfortable and how we will help you through it.

Conditioning is the preparation step that happens just before the new stem cells are given. It usually involves high-dose chemotherapy, and sometimes radiation, given over several days. Conditioning has two purposes: to destroy as many diseased cells as possible and to make space in the marrow so the healthy new cells can settle and grow. It also calms the immune system so it does not reject donor cells in an allogeneic transplant. This phase can cause side effects such as tiredness, nausea and a higher infection risk, which the team manages carefully. Your oncologist will choose a conditioning plan suited to your disease, age and general health.

We want to be transparent. At CION, our role is to evaluate whether a transplant is right for you, present your case to a tumour board, and coordinate your care with the right specialists. During a detailed 45-minute consultation, a senior oncologist reviews your reports and explains your real options in plain language. We order no unnecessary tests and are transparent about transplant cost, because decisions here are made for healing, not billing. If a transplant is the right path, we guide you and your family through eligibility, donor matching considerations and the steps ahead. To understand exactly how your care would be arranged, please speak with our team.

Like any major treatment, a transplant carries risks that your team will discuss openly. In the early weeks, low blood counts raise the risk of infection, bleeding and anaemia, which are managed with medicines, transfusions and protective care. After an allogeneic transplant, graft-versus-host disease can occur when donor cells react against your tissues; this can be mild or serious and is treated promptly. Other possible effects include organ strain, fertility changes and a delay in immune recovery. The risk level depends on your age, health, disease and type of transplant. A senior oncologist will explain your individual risks honestly so you can make an informed decision with your family.

Eligibility is decided after a careful work-up, not by a single test. Doctors assess your disease type and how it has responded to treatment, then check that your heart, lungs, kidneys and liver are healthy enough to handle the procedure. Your age and overall fitness also matter, as does whether a suitable donor is available for an allogeneic transplant. At CION, this evaluation is reviewed by a tumour board so the recommendation reflects a team decision, not one opinion. We will explain clearly whether a transplant is suitable for you, and if it is not, we will discuss other options. Sharing your recent reports is the best first step toward a clear answer.